Skip to main content
. 2023 Feb 23;14:1041. doi: 10.1038/s41467-023-36683-x

Fig. 1. Seronegative gB/MF59 recipients develop humoral responses against novel epitopes in gB.

Fig. 1

a IgG levels against 15-mer peptides spanning gB(645–703) (Towne) in seronegative vaccine recipients after the second dose of the vaccine. Microarrays were scanned using a high-resolution fluorescence scanner. For each spot, mean signal intensity was extracted (between 0 and 65535 arbitrary units). The MMC2 equals the mean value of all three instances on the microarray. Each peptide is represented by the symbol in the key (b) Anti-AD-6 levels (gB(648–697) Towne) in 32 seronegative recipients of vaccine (V+) or 3 placebo (V−) measured by ELISA and represented as absorbance at 450 mm. Cutoff calculated as average of 2 seronegative sera plus 4 standard deviations. c Anti-AD-6 IgG (gB(648–697) Towne) levels in 102 CMV seropositive volunteers measured by chemiluminescence immunoassay (CLIA). Cutoff was determined by averaging values of seven sera samples from CMV seronegative volunteers plus 4 standard deviations. Values are expressed as relative light units (RLU).